Cloud-based Software for the Global Life Sciences Industry

Veeva is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry. Our solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance.

Latest News

April 15, 2021 Parexel and Veeva Partner to Accelerate Clinical Trials
  Parexel and Veeva Systems (NYSE: VEEV) today announced a strategic collaboration to accelerate clinical trials through technology and process innovation. The unique collaboration combines the best of each company's experience across thousands of studies worldwide – Parexel as a leading clinical research organization (CRO) and Veeva as the technology innovator powering trials – to improve study efficiency and get new therapies to patients faster. As part of the partnership, Parexel is standardizing on Veeva's suite of clinical operations applications, including Veeva Vault eTMF , Vault CTMS , and Vault Study Startup to streamline operations. Veeva Vault CDMS  for clinical data management will also become a standard offering available from Parexel to its customers.    With insights from sponsors, sites, and patients, the companies will collaborate to continuously improve Veeva's cloud technology and Parexel's processes for delivery of...
March 2, 2021 Veeva Announces Fourth Quarter and Fiscal Year 2021 Results
Fiscal Year 2021 Total Revenues of $1,465.1M, up 33% Year-over-year; Q4 Total Revenues of $396.8M, up 27% Year-over-year; Fiscal Year 2021 Subscription Services Revenues of $1,179.5M, up 32% Year-over-year; Q4 Subscription Services Revenues of $322.8M, up 27% Year-over-year Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2021. “It was a transformational year for life sciences and for Veeva. The industry delivered breakthroughs in diagnostics, therapies, and vaccines during a global pandemic,” said CEO Peter Gassner. “I am proud of the Veeva team's execution and commitment. We innovated faster than ever before to help our customers adapt quickly in support of doctors and patients around the world.” Fiscal 2021 Fourth Quarter Results: Revenues : Total revenues for the fourth quarter were $396.8 million, up from $311.5 million one year...

Investor Contact

Ato Garrett

Email Alerts

Email *
Mailing Lists *

Enter the code shown above.